포스터 다운로드_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

top

Please input keywords

KR

사회적 책임

합작연구개발

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

동물/세포 모델

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology service

Therapeutic area

Types of services

유전자 편집

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

자료 다운로드

포스터 다운로드

홍보센터

뉴스 및 각종 자료 열람

논문게재실적

자료 다운로드

포스터 다운로드

제품정보 다운로드

AACR 2024: Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies

AACR 2024: BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors

AACR 2024: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity

AACR 2024: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

AACR 2024: A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

AACR 2024: BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy

AACR 2024: A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model

AACR 2024: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

AACR 2024: TIL analysis demonstrates different mechanisms underlying PD-1 resistance in animal models

1 … 3 4 5 6 7 … 14